Ginkgo Bioworks is shaking up the pharmaceutical world with a groundbreaking collaboration! The company has joined forces with Deep Origin on a 4.5-year mission to revolutionize drug safety predictions. But here's where it gets exciting: they've secured funding from ARPA-H's CATALYST program, led by the brilliant Dr. Andy Kilianski.
The project, named PREDICTS, aims to create a cutting-edge computational platform to enhance drug safety. Ginkgo's role is pivotal, utilizing its 'Datapoints' platform to generate extensive, high-quality data sets. These datasets will train AI models to predict drug responses, covering small molecule drugs and genetic variations across various cell and tissue types. The data will include specific toxicity endpoints, DRUG-seq transcriptomics, and cell painting, offering a comprehensive view of cellular behavior.
"Working with the PREDICTS team is a privilege," said Jesse Dill, a senior director at Ginkgo. "Their vision is inspiring, and we're thrilled to contribute our expertise in cellular response data to this game-changing initiative." George Pilitsis, another Ginkgo director, echoed this sentiment, emphasizing the team's enthusiasm for pushing the boundaries of multi-omics data generation and drug discovery.
Dr. Natalie Ma, from Deep Origin, highlighted the impact of Ginkgo's high-throughput in vitro platforms, enabling large-scale data generation for modeling diverse cell types in tissues and organs. This partnership showcases Ginkgo's dedication to interdisciplinary collaborations and its prowess in generating structured datasets for small molecule drug development.
Ginkgo Bioworks is a trailblazer in making biology more accessible. They offer customizable R&D solutions, laboratory automation, and AI-powered data generation. To learn more about their innovative offerings, visit their website and explore their social media channels. But beware, there's a catch: Ginkgo's forward-looking statements come with risks and uncertainties. Investors, take note! The company's success hinges on various factors, from market volatility to technological advancements and legal proceedings. Will Ginkgo's ambitious vision become a reality? Only time will tell, and the journey promises to be captivating.
